Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02523313 |
Recruitment Status :
Completed
First Posted : August 14, 2015
Last Update Posted : December 13, 2021
|
Sponsor:
Prof. Dr. med. Dirk Schadendorf
Information provided by (Responsible Party):
Prof. Dr. med. Dirk Schadendorf, University Hospital, Essen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | June 27, 2021 |
Actual Study Completion Date : | June 27, 2021 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):